Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 18/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | ADAM10 | O14672 | 3/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10276389 | 0.77 | ADAM17 (0.62) | ADAM17ADAM10MMP3MMP1ADAM9 | |
| SCHEMBL15327676 | 0.77 | ADAM17 (0.62) | ADAM17ADAM10MMP3MMP1ADAM9 | |
| SCHEMBL15327690 | 0.73 | ADAM17 (0.50) | ADAM17ADAM10MMP3MMP1ADAM9 | |
| SCHEMBL1503578 | 0.73 | ADAM17 (0.50) | ADAM17ADAM10MMP3MMP1ADAM9 | |
| SCHEMBL6842741 | 0.72 | DRD4 (0.59) | OPRD1ITGB3ITGA2B | |
| SCHEMBL16829430 | 0.70 | KDM4E (0.64) | — | |
| SCHEMBL7302879 | 0.70 | OPRD1 (0.60) | OPRD1 | |
| SCHEMBL22122851 | 0.70 | SMN1; SMN2 (0.63) | OPRD1 | |
| SCHEMBL12076907 | 0.69 | ADAM17 (0.71) | ADAM17ADAM10MMP3MMP1ADAM9 | |
| SCHEMBL1503597 | 0.69 | ADAM17 (0.71) | ADAM17ADAM10MMP3MMP1ADAM9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115102-B2 | N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-08-25 | — | — | US | disclosed |